Dicerna Pharmaceuticals, Inc. announced that two abstracts related to the Companys clinical development programs have been accepted for poster presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® taking place Nov. 12-15, 2021. The first abstract provides clinical data from the Companys Phase 1 trial of belcesiran, an investigational GalXC RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD). Session: Metabolic and Genetic Disease: Hemochromatosis, Wilson Disease, a-1 Antitrypsin Deficiency; Poster Title: Belcesiran Was Well-Tolerated and Reduced Serum AAT Levels in Healthy Volunteers (Phase 1 Interim Results); Poster #: 27962; and Abstract #: 1549. An additional abstract provides results of a subpopulation pharmacokinetic and safety analysis from the Phase 1 trial of RG6346 (RO7445482), an investigational GalXC RNAi therapeutic that Dicerna is developing in collaboration with Roche for the treatment of chronic hepatitis B virus (HBV) infection. Session: Hepatitis B: Therapeutics: New Agents; Poster Title:The Pharmacokinetic and Safety Profiles of RO7445482 siRNA Are Similar Between Asian and Non-Asian Healthy Volunteers and Chronic Hepatitis B Patients in a Phase 1 Study; Poster #: 28577; and Abstract #: 850. Both posters will be available for the duration of the meeting beginning on Friday, Nov. 12.